跳到正文
原文
Endpoints News 生物医药· Ryan Cross·· 22 天前AI 评分54

FDA 为个体化基因编辑疗法勾画审批路径

FDA charts path for approval of individualized gene editing therapies

AI 导读

FDA 梳理了药企为针对单人致病突变的个体化基因编辑疗法寻求监管批准可采取的步骤。可见部分未展开具体步骤内容与适用范围。

正文

The FDA has out­lined steps drug­mak­ers can take to seek reg­u­la­to­ry ap­proval for gene edit­ing med­i­cines tai­lored to fix a sin­gle per­son’s dis­ease-caus­ing mu­ta­tion.
The …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

来源:Endpoints News 生物医药 · endpoints.news